Answers are grounded in this paper and cite their sources.
We were able to confirm our previous observation that DAC therapy was effective in half of the studied patients with high-risk myelodysplastic syndrome and is especially active in the patients with the worst prognoses. Myelosuppression was the only major adverse effect observed.
No takes yet. Share an insight, caveat, or question.
Wijermans et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: